迪哲(江蘇)醫(yī)藥股份有限公司

迪哲醫(yī)藥（股票代碼：688192）是一家創(chuàng)新型生物醫(yī)藥企業(yè)，專注于惡性腫瘤、免疫性疾病領域創(chuàng)新療法的研究、開發(fā)和商業(yè)化。公司堅持源頭創(chuàng)新的研發(fā)理念，以推出全球首創(chuàng)藥物（First-in-class）和具有突破性潛力的治療方法為目標，旨在填補全球未被滿足的臨床需求?；谛袠I(yè)領先的轉化科學和新藥分子設計與篩選技術平臺，公司已建立了五款具備全球競爭力的產品管線，兩大領先產品處于全球關鍵性臨床試驗階段，其中一款已獲批上市。 Dizal Pharmaceutical Co., Ltd (Ticker: 688192 ) is a commercial stage biopharmaceutical company. At Dizal we aspire to discover and develop differentiated therapeutics for the treatment of cancer and immunological diseases. Building on our extensive expertise in translational science and molecular design, we have established an internationally competitive portfolio of five clinical-stage assets with two leading assets in global pivotal studies and one already approved.